Clinical trial
Study Of GW679769 In Major Depressive Disorder
NCT00102492 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00102492 |
|---|---|
| Title | Study Of GW679769 In Major Depressive Disorder |
| Official title | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major, Major Depressive Disorder (MDD) |
| Intervention type | Drug |
| Interventions | GW679769 |
| Enrollment | 356 |
| Start date | Oct 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jan 31, 2005 |
| Last update posted | Apr 16, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: